Fig. 2: Comparing ASGARD to bulk-cell-based repurposing methods.
From: ASGARD is A Single-cell Guided Pipeline to Aid Repurposing of Drugs
The receiver operating characteristic (ROC) curves and area under curve (AUC) scores of the ASGARD, on advanced metastatic breast cancer, acute lymphoblastic leukemia, and coronavirus disease 2019 (COVID-19), respectively. a Comparison among different DE analysis methods Limma (red), DESeq2 (light blue), Seurat (green), and edgeR (blue) using the best-performing mode in each. b Comparison of ASGARD (red) and bulk-sample based drug repurposing methods: CLUE (blue), and DrInsight (green), using the same three diseases as in a. The single-cell RNA-Seq data were aggregated to pseudo-bulk RNA-Seq data as the input of the bulk-sample based methods. Source data are provided as a Source Data file.
